INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2022, Supplement 3

Cardiovasc Metab Sci 2022; 33 (S3)

Kidney and heart damage associated with high blood pressure: strategies for early detection in primary care settings

Palomo-Piñón, Silvia; González-Coronado, Vidal José; Antonio-Villa, Neftali Eduardo

ABSTRACT

High blood pressure (HBP) is a highly prevalent metabolic condition in the Mexican population that produces multisystem involvements with heterogeneous effects among individuals. In the long term, the complex relationship between cardiometabolic risk factors promotes the development of Atherosclerotic Cardiovascular Disease (ASCVD). A critical associated complication is the cardiorenal effect related to HBP, which leads to a high burden of chronic kidney disease (CKD) and heart damage. Hence, the importance of promptly identifying cardiorenal impairments at early stages of the disease within primary care (PC) personnel. This work aims to point out the early diagnosis strategies for kidney and heart damage in patients with HBP to systematize their search in a PC setting. A moderate decrease in the estimated glomerular filtration rate (eGFR) and the presence of any degree of albuminuria are excellent markers for screening kidney damage. Left ventricular hypertrophy (LVH) assessed with either an electrocardiogram (EKG) or echocardiography had well-defined criteria and validated indexes to identify cardiac damage. Finally, a severe complication is heart failure (HF), which needs to be fundamentally based on clinical and EKG findings. A correct interpretation of an EKG makes an accurate diagnosis in 75% of patients living with HF. The proper implementation of these strategies in a PC scenario is crucial to identify cardiorenal impairments and reduce the long-term incidence of ASCVD in the Mexican population.
  FULL TEXT PDF  

Keywords

High blood pressure kidney damage heart damage




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • Metformin in the management of non-alcoholic fatty liver disease: current...
    2025, Vol.36, Núm. 1
  • Leptin: a description of its intriguing biology. A review. Part I
    2025, Vol.36, Núm. 1
  • Statement from the Presidency of ANCAM and its Editorial Committee
    2025, Vol.36, Núm. 1
  • Inflammation indices in chronic stable coronary artery disease
    2025, Vol.36, Núm. 1
  • The MACARENHA connection: a holistic approach to understand and fight the...
    2025, Vol.36, Núm. 1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3

Cardiovascular and Metabolic Science Vol. 33, Num. S3, Julio-Septiembre 2022. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 https://www.cardiovascularandmetabolicscience.org.mx/ ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail addresses: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-061316491900-203. ISSN: 2683-2828 versión impresa y 2954-3835 versión electrónica. Ambos otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 04 de abril de 2024.

 

2025     |     https://www.cardiovascularandmetabolicscience.org.mx/